Krux Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 3.00 Cr
as on 17-11-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.77 Cr
as on 17-11-2024
- Satisfied Charges ₹ 31.49 Cr
as on 17-11-2024
- Revenue 28.11%
(FY 2023)
- Profit 108.21%
(FY 2023)
- Ebitda 150.23%
(FY 2023)
- Net Worth 2.71%
(FY 2023)
- Total Assets 12.36%
(FY 2023)
About Krux Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹11.77 Cr. The company has closed loans amounting to ₹31.49 Cr, as per Ministry of Corporate Affairs (MCA) records.
Salim Chopdar and Imran Siroha serve as directors at the Company.
- CIN/LLPIN
U24302GJ2016PTC094103
- Company No.
094103
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2016
- Date of AGM
16 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Valsad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Krux Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Salim Chopdar  | Director | 19-Apr-2024 | Current |
| Imran Siroha | Director | 17-Oct-2016 | Current |
Financial Performance of Krux Pharma.
Krux Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.11% increase. The company also saw a substantial improvement in profitability, with a 108.21% increase in profit. The company's net worth moved up by a moderate rise of 2.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Krux Pharma?
In 2023, Krux Pharma had a public holding of 66.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 25 Aug 2023 | ₹11.77 Cr | Open |
Hdfc Bank Limited Creation Date: 03 Jul 2021 | ₹11.59 Cr | Satisfied |
Indian Bank Creation Date: 09 Oct 2018 | ₹9.95 Cr | Satisfied |
How Many Employees Work at Krux Pharma?
Krux Pharma has a workforce of 42 employees as of Apr 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krux Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krux Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
